Glaukos Corporation
GKOSHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeGlaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and. The company carries a $10.55B market cap, placing it firmly in the large-cap category. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Market Cap
$10.55B
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
342.16
EPS (TTM)
$-3.26
EPS (Fwd)
$0.52
ROE
-26.0%
ROA
-5.2%
Cash
$286.2M
Total Debt
$107.6M
Free CF
$15.5M
52W Change
139.6%
Annual Financials
Cash vs Debt
Where GKOS stands vs its 150-day and 200-day moving averages
As of the October 7, 2026 close, GKOS finished 13.80% above its 150-day moving average ($141.99) and 19.23% above its 200-day moving average ($135.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GKOS overbought or oversold?
At the October 7, 2026 close, GKOS's RSI(14) was 46.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $286.2M in cash comfortably exceeding the $107.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $15.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -26.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $282.9M (2022) to $507.4M (2025), reflecting a 79% increase over the period.
The relatively low beta of 0.69 suggests GKOS is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing GKOS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.